Worldwide, tuberculosis claims about 1.5 million victims per year. It is one of the most dangerous diseases caused by bacteria. The increasing spread of multi-resistant strains of the pathogen is particularly worrying. A group of researchers and entrepreneurs is currently developing an antibiotic with public funding that is also effective against resistant strains.
A promising active substance against tuberculosis is now about to undergo clinical trials. The active ingredient is being manufactured by HAPILA GmbH, a portfolio company of bm|t.
https://youtu.be/